Hyqvia Market Report 2026

Hyqvia Market Overview

• The Hyqvia market growth in the historic period has been driven by limitations of intravenous ig therapy, high infection risk in pi patients • Market expansion is supported by rising diagnosis of primary immunodeficiency, expansion of home healthcare services • Growth Driver: Impact Of Rising Autoimmune Diseases On The Growth Of The Hyqvia Market • Market Trend: FDA Approval For Immune Globulin Infusion As Maintenance Therapy For CIDP • North America was the largest region in 2025 and Europe is the fastest growing region.

What Is Covered Under Hyqvia Market?

Hyqvia is a combination therapy for primary immunodeficiency (PI) in adults and children, consisting of human immune globulin (IgG) to provide essential antibodies and recombinant human hyaluronidase (rHuPH20) to enhance absorption under the skin. Administered subcutaneously once every three to four weeks, it allows for larger, less frequent infusions at a single site, improving patient convenience compared to traditional therapies. Hyqvia helps reduce infection risk in individuals with low IgG levels due to PI, with common side effects including injection site reactions, headache, and flu-like symptoms. The main types of hyqvia patient demographics include pediatric and adult patients. Pediatric patients are individuals who are under the age of 18 and require specialized care for growth and development. It is distributed through various channels, including hospitals, specialty pharmacies, home healthcare providers, and retail pharmacies, and is applied for primary immunodeficiency, chronic inflammatory demyelinating polyneuropathy, and other indications.

What Is The Hyqvia Market Growth Forecast?

The growth in the forecast period can be attributed to rising diagnosis of primary immunodeficiency, expansion of home healthcare services, increasing pediatric pi management, preference for long interval dosing, growth in specialty pharmacy distribution. Major trends in the forecast period include shift toward less frequent immunoglobulin infusions, growing adoption of home based infusion therapies, rising demand for combination immunotherapy products, improved patient convenience in pi treatment, expansion of subcutaneous immunoglobulin use.

Global Hyqvia Market Segmentation

1) By Patient Demographics: Pediatric Patients, Adult Patients 2) By Distribution Channel: Hospitals, Specialty Pharmacies, Home Healthcare Providers, Retail Pharmacies 3) By Application: Primary Immunodeficiency, Chronic Inflammatory Demyelinating Polyneuropathy, Other Applications

What Are The Drivers Of The Hyqvia Market?

The growing prevalence of autoimmune diseases is expected to drive the growth of the hyqvia market going forward. Autoimmune diseases are conditions in which the immune system mistakenly attacks healthy cells, tissues, or organs, leading to inflammation and dysfunction. Autoimmune diseases are rising due to a combination of factors, including genetic predisposition, environmental triggers, changes in diet, increased exposure to pollutants, and improved diagnostic capabilities. Hyqvia is used for autoimmune diseases as it delivers immunoglobulin therapy, which helps modulate the immune system and minimize abnormal immune responses that target the body’s own tissues. For instance, in May 2023, according to the NIHR Imperial Biomedical Research Centre, a UK-based government research institute and agency, the study analyzed anonymized electronic health records from 22 million UK individuals to examine 19 common autoimmune diseases, which affect roughly 10% of the population, 13% of women and 7% of men. Therefore, the growing prevalence of autoimmune diseases is driving the growth of the hyqvia industry. The increasing healthcare investment is expected to propel the growth of the hyqvia market going forward. Healthcare investment refers to the allocation of financial resources into healthcare-related businesses, technologies, research, and infrastructure to improve patient outcomes, support innovation, and drive industry growth. Healthcare investment is rising due to increasing demand for advanced medical treatments, technological innovations, an aging population, and a focus on improving global healthcare access and outcomes. Healthcare investment positively impacts HYQVIA by supporting its continued development, regulatory approvals, and broader access, ultimately driving adoption for treating immunodeficiency and CIDP. For instance, in April 2025, according to the American Medical Association, a US-based non-profit organization, U.S. health spending climbed by 7.5% in 2023, reaching $4.9 trillion, or $14,570 per person, marking a sharp acceleration compared to the 4.6% increase recorded in 2022. Therefore, the increasing healthcare investment is driving the hyqvia industry.

Key Players In The Global Hyqvia Market

Major companies operating in the hyqvia market are Takeda Pharmaceutical Company Limited

Global Hyqvia Market Trends and Insights

The ket trend in the hyqvia market is focusing on developing innovative products, such as immune globulin infusion, to treat chronic inflammatory demyelinating polyneuropathy (CIDP) and primary immunodeficiency (PI). Immune globulin infusion is a treatment that involves administering antibody-rich plasma proteins to address immune deficiencies and autoimmune disorders. For instance, in January 2024, Takeda Pharmaceutical Company Ltd., a Japan-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its product, HYQVIA® (immune globulin infusion 10% [human] with recombinant human hyaluronidase), for use as a maintenance therapy for adults with chronic inflammatory demyelinating polyneuropathy (CIDP). The FDA approval permits HYQVIA to be used to prevent relapses of neuromuscular disability and impairment caused by CIDP, a rare neuromuscular disorder that affects approximately five to seven individuals per 100,000 in the U.S.

Regional Insights

North America was the largest region in the hyqvia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Hyqvia Market?

The hyqvia market consists of sales of hematology medications, gastrointestinal medications, vaccines, and biosimilars. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hyqvia Market Report 2026?

The hyqvia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hyqvia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.